权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Sedative-Hypnotic Use Patterns and Risk for Cognitive Decline and Alzheimer's Disease

镇静催眠药的使用模式以及认知能力下降和阿尔茨海默病的风险

基本信息

批准号：
10558721
负责人：
Christopher Norfleet Kaufmann
金额：
$ 12.77万
依托单位：
UNIVERSITY OF FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-02-15 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10558721
关键词：
Acceleration Address Aging Alprazolam Alzheimer disease prevention Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Applied Research Automobile Driving Benzodiazepines Categories Chronic Clinical Cognition Cognitive Cognitive aging Cohort Studies Complement Data Data Analyses Dementia Development Diagnosis Disease Outcome Doctor of Pharmacy Doctor of Philosophy Elderly Eszopiclone Funding Geriatrics Goals Growth Guidelines Health Services Health Services Research Health and Retirement Study Impaired cognition Incidence Knowledge Link Medicare claim Medicine Mentors Mentorship Outcome Patients Pattern Pharmaceutical Preparations Pharmacologic Substance Prevention Probability Psychiatry Radiation Recommendation Research Research Personnel Research Project Grants Risk Safety Science Sleep Sleep disturbances Sleeplessness Statistical Models Substance abuse problem Training Training Activity Training Programs Training Support United States Variant Work Zaleplon alternative treatment analytical tool career clinical diagnosis cognitive impairment no dementia cognitive performance cognitive testing design doctoral student experience hypnotic medication safety mid-career faculty professor sedative side effect zolpidem

项目摘要

ABSTRACT This proposed K01 application will support the training of Christopher N. Kaufmann, PhD, MHS, in pursuit of his career goal of becoming an independently funded Alzheimer’s disease health services researcher. This application consists of two complementary components: a) a research project examining trajectories of cognitive aging and Alzheimer’s disease and dementia outcomes associated with use of sedative-hypnotic medications, and b) a 5-year comprehensive training plan comprised of mentorship, didactic and professional development opportunities, and experiential training activities designed to address three gaps in his past training: a) cognitive aging and Alzheimer’s disease research, b) utilizing and analyzing administrative data (including Medicare claims), and c) longitudinal data analysis to statistically model aging trajectories, all culminating in the submission of an R01 application in years 3-5. In the proposed research project, Dr. Kaufmann will examine how use of sedative-hypnotic medications are associated with trajectories of cognitive performance, transition across cognitive status categories (e.g., normal cognition, cognitively impaired but not dementia, and dementia status), and incidence of Alzheimer’s disease among other related dementia diagnoses over a 12-year period from 2006 to 2018. To answer these questions, the project will take advantage of the NIA-funded Health and Retirement Study with linked data from Medicare claims. The project is supported by a strong interdisciplinary mentorship team with expertise in geriatrics, cognitive aging and Alzheimer’s disease, health services research, longitudinal data analysis, sleep, and pharmaceutical sciences. Alison Moore, MD, MPH, Chief of the Division of Geriatrics, and expert in substance abuse in seniors with extensive contacts within the geriatrics and aging field, Mark W. Bondi, PhD, Professor in the Department of Psychiatry, with extensive research in cognitive assessment and Alzheimer’s disease, and James D. Murphy, MD, MS, Associate Professor in the Department of Radiation Medicine and Applied Sciences and expert in use of Medicare claims data, will serve as the mentors of this application. Their mentorship will be complemented by that of Xin Tu, PhD, a senior biostatistician with extensive experience in longitudinal data analysis, Adam P. Spira, PhD, an expert in sleep disturbances and Alzheimer’s disease outcomes, and Grace M. Kuo, PharmD, MPH, PhD, a medication safety expert. The research project and complementary training plan will provide Dr. Kaufmann with hands-on experience in utilizing administrative data with longitudinal data to answer questions important to cognitive aging and ultimately Alzheimer’s disease and dementia prevention efforts. Further, the proposed work will provide Dr. Kaufmann with the training needed to propel his career towards becoming an independently R01-funded Alzheimer’s disease researcher.

摘要 K 01应用程序将支持Christopher N.考夫曼，博士，MHS，在追求他的职业目标是成为一名独立资助的阿尔茨海默病健康服务研究人员。这应用程序由两个互补的组成部分：a）一个研究项目，研究认知的轨迹与使用镇静催眠药物相关的衰老、阿尔茨海默病和痴呆结局，以及B）一个为期5年的综合培训计划，包括导师制、教学和专业发展机会和体验式培训活动，旨在解决他过去培训中的三个差距：a）认知老龄化和阿尔茨海默病研究，B）利用和分析管理数据（包括医疗保险索赔），以及c）纵向数据分析，以统计建模老化轨迹，所有这些都在提交中达到顶峰 R 01应用程序在3-5年。在拟议的研究项目中，考夫曼博士将研究如何使用镇静催眠药物与认知表现的轨迹相关，认知状态类别（例如，正常认知，认知受损但非痴呆，和痴呆状态），从2006年开始的12年间，至2018为了回答这些问题，该项目将利用NIA资助的健康和退休计划，研究与医疗保险索赔的相关数据。该项目得到了强大的跨学科导师的支持团队在老年医学，认知老化和阿尔茨海默病，健康服务研究，纵向数据分析睡眠和制药科学艾莉森摩尔，医学博士，公共卫生硕士，老年病科主任，他是老年人药物滥用方面的专家，在老年医学和老龄化领域有着广泛的联系。 Bondi博士，精神病学系教授，在认知评估和阿尔茨海默氏病和詹姆斯D. Murphy，MD，MS，放射科副教授医学和应用科学以及医疗保险索赔数据使用方面的专家将担任本课程的导师。应用程序.他们的指导将得到Xin Tu博士的补充，Xin Tu博士是一位高级生物统计学家，纵向数据分析经验，Adam P. Spira博士，睡眠障碍和阿尔茨海默氏症专家疾病结果，和Grace M. Kuo，PharmD，MPH，PhD，药物安全专家。该研究项目和补充培训计划将提供考夫曼博士在利用行政管理的实践经验，用纵向数据回答认知老化和最终阿尔茨海默病的重要问题和痴呆症预防工作。此外，拟议的工作将为考夫曼博士提供所需的培训推动他的职业生涯成为一个独立的R 01资助的阿尔茨海默病研究人员。